Karyopharm Therapeutics Enters Material Definitive Agreement
Ticker: KPTI · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $12.5 million, $15.0 million, $103.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation
TL;DR
KaryoPharm just signed a big deal, watch for new financial obligations.
AI Summary
Karyopharm Therapeutics Inc. announced on October 10, 2025, the entry into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The company is based in Newton, Massachusetts.
Why It Matters
This filing signals a significant contractual development for Karyopharm Therapeutics, potentially impacting its financial obligations and strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and potential new financial obligations, which could introduce financial or operational risks.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- October 10, 2025 (date) — Date of earliest event reported
- Newton, Massachusetts (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Karyopharm Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one has been entered into as of October 10, 2025.
What type of financial obligation has Karyopharm Therapeutics created?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specifics are not detailed.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 10, 2025.
Where are Karyopharm Therapeutics' principal executive offices located?
Karyopharm Therapeutics' principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts, 02459.
What is Karyopharm Therapeutics' Standard Industrial Classification (SIC) code?
Karyopharm Therapeutics' Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,124 words · 4 min read · ~4 pages · Grade level 12.6 · Accepted 2025-10-14 16:11:56
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
- $12.5 million — n October 8, 2025, the Company borrowed $12.5 million under its credit and guaranty agreement
- $15.0 million — on October 8, 2025, the Company issued $15.0 million aggregate principal amount of 9.00% sen
- $103.5 million — secured convertible notes due 2028 and $103.5 million aggregate principal amount of 9.00% sen
Filing Documents
- d81116d8k.htm (8-K) — 36KB
- d81116dex41.htm (EX-4.1) — 968KB
- d81116dex42.htm (EX-4.2) — 894KB
- d81116dex43.htm (EX-4.3) — 170KB
- d81116dex44.htm (EX-4.4) — 78KB
- d81116dex45.htm (EX-4.5) — 77KB
- d81116dex46.htm (EX-4.6) — 76KB
- d81116dex101.htm (EX-10.1) — 1093KB
- d81116dex102.htm (EX-10.2) — 155KB
- d81116dex103.htm (EX-10.3) — 161KB
- d81116dex104.htm (EX-10.4) — 145KB
- d81116dex105.htm (EX-10.5) — 138KB
- d81116dex106.htm (EX-10.6) — 606KB
- d81116dex107.htm (EX-10.7) — 160KB
- d81116dex108.htm (EX-10.8) — 153KB
- d81116dex109.htm (EX-10.9) — 160KB
- g81116g00j37.jpg (GRAPHIC) — 4KB
- g81116g08b25.jpg (GRAPHIC) — 6KB
- g81116g34a85.jpg (GRAPHIC) — 5KB
- g81116g40s85.jpg (GRAPHIC) — 7KB
- g81116g86t40.jpg (GRAPHIC) — 5KB
- g81116g95t01.jpg (GRAPHIC) — 5KB
- 0001193125-25-239015.txt ( ) — 6403KB
- kpti-20251010.xsd (EX-101.SCH) — 3KB
- kpti-20251010_lab.xml (EX-101.LAB) — 18KB
- kpti-20251010_pre.xml (EX-101.PRE) — 11KB
- d81116d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Indenture (including form of Note) with respect to the Company's 9.00% Convertible Senior Notes due 2028, dated October 10, 2025, between the Company, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent 4.2 Indenture (including form of Note) with respect to the Company's 9.00% Convertible Senior Notes due 2029, dated October 10, 2025, between the Company, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent 4.3 Form of Warrant to Purchase Common Stock 4.4 Form of Warrant to Purchase Common Stock 4.5 Form of Warrant to Purchase Common Stock 4.6 Form of Pre-Funded Warrant to Purchase Common Stock 10.1 First Amendment and Waiver to Credit and Guaranty Agreement, dated October 7, 2025, by and among the Company, as borrower, the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent for the lenders party thereto and collateral agent 10.2 Note Purchase Agreement, dated October 7, 2025, by and among the Company and the other parties thereto 10.3 Form of Exchange Agreement, dated October 7, 2025, by and among the Company and the other parties thereto 10.4 Form of Exchange Agreement, dated October 7, 2025, by and among the Company and the other parties thereto. 10.5 Form of Exchange Agreement, dated October 7, 2025, by and among the Company and the other parties thereto 10.6 Sixth Amendment to the Revenue Interest Financing Agreement, dated October 7, 2025, by and among the Company and the investors party thereto, HealthCare Royalty Management, LLC as the investor representative, and HCR Karyopharm SPV, LLC, as the collateral agent 10.7 Securities Purchase Agreement, dated October 7, 2025, by and among the Company and the other parties thereto 10.8 Form of Registration Rights Agreement, dated October 10, 2025,
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: October 14, 2025 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary